Professional Documents
Culture Documents
مختصر علم الأدوية
مختصر علم الأدوية
www.syrianclinic.com
Drug receptors
: Receptor ! () molecule 2
-! ($ /0 - +
3- ) 567 4 + (... @ ? > 2 $
;
:
4
4+
7-: BC- 0A
A )!A
2 /0 (:
. 5
A76 J 5
A I.
. 5
AA 3. G $
. 5
AA 3C
$7Tyrosine Kinase.
NN O . L-dopa 5NNP : precursor QNN NN
> dopamine !NN:4(-NN
T) 4? V U
O 40
4
? (. !:
. 3NNP NNA >70NN 3NNP carbidopa 5NNP synthesis enzymes70NN
] dopamine A > 7 - L-dopa 40BC 0:? VDopa )DDC3P 40
3Y 0: (Decarboxylase
> U !: 4(-T.[4
. J7A $ 567 $A[ 4P U
Reserpine?
A-6 5A 3^[ _Y ] $
- U :-: U
`".
!
: A
A
- $ 2 U
: ATP 6O 27 6
c?+ Y transporters 3 $ c?+7 5:Y +0P
7
:.depletion
. 3T7 : 567 amphetamine 5P 4 g U J7 4
3
.reuptake.
. 3P : 567 5P 4 #
#$ 3P Q : 567) 4 :
5 $ ($:.
. :
A - 5P ]TA
.
. 3T7
A -#%
5P ]TA
#%.
. *(
A ? - Y autoreceptors70 :.567
www.syrianclinic.com
r & > 7A
Anxiolytics and Sedatives
:4 5AT
. Benzodiazepines (BDZs) $
$
. Barbiturates #
P- 4 $
2
5A( serotonergic system)
.($
A I $
:Tolerance 7 .I
2
u $ J
: ? U-
] -7
- BC m67
A
! Y
({ )
u c? / { -
u r uA - -
-7Y) BC
x; -y
www.syrianclinic.com
( 6
2-
BC 0A $+I - BB? V| 0 2
u
22
5:
BC 0A.
A -:
:5A:
( Q 0T7 + A ]@
Y - 2 .y
A - - ) P
; +
: 2 ( Y
4
: !
-:Y +7
) ;(( . A + 3T7
: !
$?c
.
$]A . -: J $; 4Y; 5
A - ) desensitization m:(
/
Y
A ( - t>
A ]
A -
7; ; gs
?
2A $ Down regulation? c t ; -
A ; 4Y
A 4Y :
$ 2
5:
u- > 4
; 4Y; 5
A -
4
: !
.
<: :
7
! --: 5:
5A: -BC - x JAu
BC PAY
3P Y 4;7
u 7
-: mg 2 3P 4;7 .5 U 5 3Y 5A:
BC
5 A r
^
BC 3PA
x;7 7] $A0 ? c.
www.syrianclinic.com
BC .-u 2
r07]7 2
r07 $] ) $`Y+ T( ]7 $cBC
.
- $ 4;7 40
A $- $ 4;7.50
-7 u>
A-
tu J06- uY
2 - Cocaine 5P
-Y Morphine U0; x- -6 U0 5- U:- u
Q;_
u
2
2
0 _A : > Placebo A .7-A
(minor) sedative) $ J 4( -+ (major) tranquilizer ;>
- .
t$
- ? c
u |;7A u anxiety r
u
6 2
sedation
u
2 t .
- -
A -A $! 5 5
u
.-
* _ 77
>A Diazepam 5P Lorazepam ?
A 4Y
GI ChlordiazepoxideD 7D #7%.
!
$
$
g -A ? c
2 5A
3P 4Y +u Limbic System 4A? c7 4
. hippocampus, septum amygdala,
$
$ F< ) GABAA L$ #%( GNI ( NM
N1 . GABA Q ) *( ( $ #% T F1 N#R # #% R
U
I $ V$ L ) hyper-polarization $7+R H# &
U $7+
(NR G*
(
U M.Y+
<: :Notes
7 Y g 4Y 5A $ 77
:
$
$ :
I ( I Indirect Agonists D +# $Z [1 #% -
+O 5
A 5 M 1 5
A GABA? ;
/7.
# :
I Full agonist + G G$Z [1 #% ^_ $
7!
GABAY Y3
+ g Q + A$#R ## F R@ A
U 2
A$ >
0.
P-
T
) BZDs 77( 4Y-.
77 $ 4Y r7 ? Y U g 4Y
BZDs5A Q! - 77
4Y NA (noradrenaline) 5A
3P- rO $
V 3P 7 4Y !7
ceruleus locus?
BC U0 567 GABA 4
.U
?Y V $ g 4Y
BZDs 5AI 20 U> r )g
Buspirone A7(.
+ - 7 4Y rY-- 4Y^->
-7 .r
-7@ B 77
2 4Y GABA7 TY 4 +@ 2 |.
www.syrianclinic.com
- J 3
Y
- J 3 7 7 > ] 76 5PA 5]I
.5
A x; 2
J :]
Location of Action
Therapeutic Effect
Y+ M
U AZ#
V$ GH<
(
*
agitation and fearAlleviate anxiety
Amygdala
+
r $ s;
Cerebral Cortex
0[ antiepileptic actions amnesiaMental confusion
. | 5Y ( )-Y 47
Hippocampus
Spinal Cord
Mild muscle-relaxing effects
Cerebellum
s; 4 |
Brainstem
.M Y.7
:absorption & Distribution # D
.u 5 4Y
AY ?- + m
A V ?- : DZDs
: Metabolism <d
A V ?4 - $ C0 elimination O - + I 2 - DZDs t
. O BC;
.
( 5]I 2
4Y 0
: Duration of Action & half-life G1$
M
$ - !
s Oy $ UC 4;7 A A c?+ 4;7 A $
.u
Y V J
- Lorazepam A7
- Diazepam 4;7 A :*
-) Diazepam BC
Y $ P] 2
4
Lorazepam ; 4- BC
Y
:? Y
(
-
+Y ?Lorazepam $ $A P - 4Y : U Diazepam .
4A:T 7 4Y
A 5]T)4A:T 7 4Y |
U7 U7]
.( ( ;5]T
www.syrianclinic.com
-: DZDs
A Y
A ; .]
>: )confusion 5]T[0
)hallucination(4 ()agitation ,(+)restlessness (5A A >: -:
[
U A- $-+ Y : > -: r . 6
A M t1/2
Z ? ? 4Y u
>:
- -)
(6 A
s- g $; x0; t1/2 JO.
Clinical uses
5 anxiolytic . r
u : 6 Alprazolam+A]-: U7
:
% -7
$.2[A
sedative & hypnotic . BC $7P : Diazepam
u 7A $
u
A 7
u A 7- $
u : .r
2
P_ 77:
.
= t 1/2 U ( ]
A >
)7 [0 4Y
- :Flurazepam
-
:Temazepam 4Y[0 7) >
.(]A-: cBC- -
? 56 20 V? 7 -
20 . - t1/2) mg
u
(.
:Triazolam
Y U 6 BC ?
-
-7 2[A? $ +-0
5A:
tolerance? - | @ U:
2 ?
- J0
5]T
- = t1/2 . x
.mg ( .-.)
u
Side effects
Dependence>
A.
Confusion)T[0 (.(4
Drowsiness.
< Flumazenil : : ! t
A DZDs?
5AA u
A 77.
!
# :Mechanisms of Actions
g
5A
g $ 6 77 Q N+
N 2N
5NA 2N
GABAA
- 4 5A ! N76 /
Y $ MI GABA 567 ] N) (N0PA*N76 (i N
).(0T7A
M G.
#
:Pharmacological Effects of Barbiturates
*
( :CNS Q
u $N N|;7AN
-N: BCN -N+ 4NY NN
u
2N
-:
Y 7 ?
c
- -N:
u N N .?NNY V ! N
-+ NN7
-NA
2.
u
* (
iii : Respiratory Depression Giii1$NNN
3NNNPu
NNN
NNNA ]ANNN
4Y chemoreceptors
4Y x;7 NN c?N
NA
xN:O2 N
-NN7Y CO2 iiNN CO2 N
UNN7 c?NN
NNA NY
x;7NN Mii$ 3NNP c?NN
NNA
; JN CO2 N
UN7
NA
N 4 $N]N N7 u
N N
@ A CO2 2A s _A
.
< : : $u? 20 4Y 2[A: 4YTA % CO2 % & $u 2A? A
)! ($ t! $ CO2 $! 5 3T7
.x;7
(
ii+$ : Enzyme Induction Gii QNN 3NNT7NN
NNA ] NN-
NNNNY 4
NN0
m7 BC >; .
: Notes
www.syrianclinic.com
Antidepressants
E F#
:
0P . . Monoamine Oxidase Inhibitors (MAOI) MAO
| . >
` BB. TCAs Tricyclic antidepressants :
Selective Serotonin Reuptake Inhibitors 0P .
36 $>
)(SSRI
www.syrianclinic.com
:Mechanism of Action
!
5N6 N 2N UN7 N! reuptake 3N6 N
N ]NTA N+7 2N 4N 5N67 N: -N
Mono Amino N 0NN -NN rNNO $NN
-NN NNO -NN( t
NN )NN
NN7 VNNTA
$N77 )4N 5N67 N -N 4N+Y ?N N ? 0 - 3P . Oxidase MAO
.($
:$77 36 : $ $ 4
5]T
www.syrianclinic.com
7
M: Pharmacokinetics
.
m
A+ $NN )
-N7 (NAY 2N0
-N! N+ 4NY t
N] -N
N 2N (N
Y 0 4Y.
+0P MAO -? c A_ NA
+
N 4N?N 5NP NN ) tyramineN!A
4Y_ ($u 4
56 UT- 4Y $.U
7
V A
$BC I
2 :7@ A $ JY|^ 3 5]T ) 4Y 3P
(MAO
4-: ( @ Y .? V 40 2[AA $uMAO inhibitors
6 A(? .
7AA
4Y:
$ MAO!A 4Y].-
_ MAOI 3 MAO]
( O iproniazid 5P7 _
] .Carboxazone 5P
4Y 0: -! MAO7 A|+ .
BC u:
AH. Headache
$Na G. CNS stimulation
1H .EI Dry mouth
. Weight gain
Postural hypotension# ` (0.G
www.syrianclinic.com
Generic Name Trade Name Generic Trade
Name Name
Imipramine
Imipramine Tofranil Trimipramine Surmontil
c? +I $
Amitriptyline Desipramine Norpramin Protriptyline Vivactil
Au V A ?
Elavil
:BC
$ Amitriptyline Maprotiline Ludiomil
Endep
H1 .
receptor Pamelor
Nortriptyline Amoxapine Asendin
blockad Aventyl
e
Doxepin Adapin Clomipramine
H2 . Anafranil
receptor
blockad amoxapine Sinequan
Ludiomil maprotiline
e Asendin
mACh .
receptor blockade
NE reuptake inhibition .
1 receptor blockade .
2 receptor blockade .
5-HT reuptake inhibition .
5-HT2 receptor blockade .
Na Channel blockade .
:+A $ _A 2
_ + Manifestations
( ) ?delirium,(V
N)Agitation
(G Gz V
N )neuromuscular irritability
( )(coma ( u7T ) convulsions
(4;7 3P )Respiratory depression
www.syrianclinic.com
(- 4Y 3 )circulatory collapse
( Y ) Hyperpyrexia
0[ Cardiac conduction defects and severe arrhythmias
.4 5
4Y 5 t
: Pharmacokinetics - :
$]( J 5]T BBB 4+Y -! 5]T - 4Y :7 4+Y V A + )-! 5]T m
A
.
3Y +|
- 2 5 -6
;t1/2
:u BC
U7 2 @ 4
7] ]Y t cardiovascular effects
6 -
.t
tu t Orthostatic hypotension 4 >
3^| -
.4 ]t 6 4 >
3^| 2! ? @ 7
.H1 $
+
tu t sedative -+ BC -
:Drug Intreaction
.M< RM
JY A+ MAO inhibitors J : BB ? | >
`$ A$ : MAOI A .
4Y -: A ) A r
3^[ ;2 @ A $ $77
7T | 5AT
($ Y $
u7 Serotonin Syndrome $
.$ 2
4
cBC SSRI J P /[ 5-
? Y 4 |
:# N$ A -
. 3^[ ;-: : +7 J
Q # N$( 36) ? 3P TCAs :
Q +7 J
BC 2@ Y
: ?c? $
Citalopram, fluoxetine,sertraline, paroxetine
Fluoxetine Prozac
Fluvoxamine Luvox
www.syrianclinic.com
Paroxetine Paxil
Sertraline
Zoloft
citalopram
:u BC
(
N MI) decreased appetite, ( )insomnia (jZ)Anxiety,
.(1H )Tremors
.GzN Na GI GI symptoms
.M Headache
.[1B Rashes
: :<
$
( Z d
.
Q )$
`
uA $ 4P 5u
2
;0 c? Y (2nd Generation nonselective monoamine reuptake blockers
: Buproprion Oy
: Buproprion 5A
g
. 5-HT $ 36
m7
. NE $77 36
m7
. DA $- 36
m7
Adverse effects:
. anxiety, insomnia, weight loss
Contraindications:
>
Seizure disorder
4Y head injury
u I 4Y 5 electrolyte imbalance
:] 4O
alcoholism
. Alcohol
. Beta blockers
www.syrianclinic.com
. Prednisone
. Cocaine & Amphetamine withdrawal. Reserpine
) ( :
:Dopamine hypothesis
:
) Amphetamine
schizophrenia
(.
) L-dopa ( apomorphine bromocriptine
) (dopamine agonist
.schizophrenia
schizophrenia .
pathways
.
) VTA Ventral
(Tegmental Area schizophrenia
neuroleptics
major tranquillizers
:
( ) Dopamine Antagonists :( D2
( :Serotonin Antagonists
"!
:
Phenothiazines :
chlorpromazine -
fluphenazine -
Phenothiazine prochlorperazine -
)(chlorpomazine thioridazine -
promazine -
www.syrianclinic.com
)Butyrophenones (haloperidol
:Butyrophenones
haloperidol -
Thioxanthines
thiothixene -
:
.Aliphatic compounds (
(
Piperidi
Group Drug Trade name .nes
Piperazi (
Chlorpromazine (Thorazine, Largactil)
.nes
Aliphatic Promazine :$&
compounds
Triflupromazine Vesprin
Methotrimeprazine Nozinan
Mesoridazine Chlorprom
Piperidines
Thioridazine Mellaril azine
Fluphenazine
Perphenazine
Piperazines
Stemetil
Prochlorperazine
Trifluoperazine Stelazine
.
.
www.syrianclinic.com
)'+
.,/0,
.
.
.
.
.
3 2" 5 0:
Therapeeutic index
:
: .
Chlorpromezine-) antimuscarinic
.(Thioredazine
) (.
. Sedation
) (Extrapyramidal )
Dystonia Tremor ( Rigidity
. Dyskinesia
) (.
D2 ) ( Endocrine
.
&:$
)
(.
6+:
P-450 .
www.syrianclinic.com
Haloperidole dicanoate )(
.
Atypical antipsychotics
clozapine
.
? > : Pathology
substantia nigra compacta
) .
%. .(%
www.syrianclinic.com
melanins .
.
AB :Syptoms
TRAP
) Tremor T( : .
) Rigidity R ( .
) Akinesia A ) (
(.
)
: Postural disturbance P .
) bradykinesia
(.
:Treatment 2C
:
.
:Transplantation substantia
nigra compacta ......
Stem cells .
:
L-Dopa
MAO
www.syrianclinic.com
COMT
) (L-Dopa
) (MAOI,COMTI
). (dopamine agonists
:
.
.
2C+:
:L-Dopa -
L-Dopa .
BBB .
: % L-Dopa
% L-
Dopa .
striatum L-Dopa .
:
BBB
L-Dopa .
AB 2" : L-Dopa
L-Dopa
:
)( ) (.
) ( .
) (. freezing episode
fluctuation L-Dopa ) L-
Dopa ( L-Dopa
.L-Dopa
www.syrianclinic.com
A :dyskinesia E L-Dopa
) dystonia ( ) chorea (
dyskinesia .
chorea
L-Dopa
L-Dopa
dystonia
dyskinesia L-Dopa
.
:
L-Dopa
L-Dopa AADC
BBB
. AADC .caribdopa, benserazide
www.syrianclinic.com
G -
"& +Dopamine receptor 9
:antagonists
bromocriptine : :pergolide D1 ) D2
( L-Dopa
L-
Dopa .
) ( )
(.
ropinerole pramipexole
) ( .
% .
H"I - :MAOB
MAO
)
( L-
Dopa L-Dopa .
deprenyl .L-Dopa
MAOI
.
:
MAO .MAOB
MAO .MAOA
www.syrianclinic.com
H"I - :COMT
COMT (catechol-O-methyl
) transferase 3-methoxy tyramine
)) (3-MT ( . L-Dopa )
( L-Dopa . 3-O-methyl-dopa
entacarpone, tolcarpone
8 :Mechanism
cerebral cortex. hippocampus
:
) (depolarization cortex
cerebral hippocampus :
. ) Glutamic acid
(.
. ) GABA (.
. K Na , Ca .
+ + 2+
www.syrianclinic.com
ANTICONVULSANTS (
)
!"
()
*+)
/0#1
4 :%"
!' &
#$
:
Action on Ion Enhance GABA Inhibit EAA
Channels Transmission Transmission
Z#$
I (
*
L+$
Na+ Felbamate
(Benzodiazepines)
(Benzodiazepines)
Phenytoin diazepam Topiramate
Clonazepam
Carbamazepine
Lamotrigine (Barbiturates)
Topiramate Phenobarbital
Valproic acid Valproic acid
Ca+ Gabapentin
Ethosuximide Vigabatrin
Valproic acid Topiramate
Felbamate
Tiagabine
.GABA
GABA :(GBP)Gabapentin
.
. GABA :(TPM) Topiramate
. Carbamazepine
.GABA
www.syrianclinic.com
.
:
:
.
.
.
819 ?1
>=:%
GBP )..... (.
VGB ....(GABA aminotransferase) GABA-T
) SSA (.... VGB
.
TGB .
TPM .
www.syrianclinic.com
Side effects
Fatigue
.
Dizziness.
Sedation.
3
Q 9+,O:
:
:
interneurones
.enkephalin
SP Glu
SP
Glu
.
:
interneuronsdynorphin
kappa ) (Gi
.
& :$ Glu
) ( .
) ( .
:
decsending pathway :
opioid recertors GABA
GABA locus ceruleus
GABA Raphe nucleus
www.syrianclinic.com
) ( SP Glu
pain signal .
:
.
neuroaugmentation
) (
)
( .
. acupunture
.
.
www.syrianclinic.com
. :
.
. :
.
- :Urinary Tract
.
- :Respiratory Tract
)
CO2
( .
- : Cough
.
- :miosis
)( .
.
- :Pinpoint pupil
) (.
- :
:
. . .cold body
. : )FSH (Follicle stimulating Hormone
b- ACTH (Adrinocortic Trophic Hormone) LH Hormone)(Luteine
.(beta-Endorphin) END
. ) ( :
anorexia
.
www.syrianclinic.com
:Stress -
stress:
-Endorphin
ACTH
Pro-
)(opiomelanocortin
ACTH -
.Endorphin
ACTH -Endorphin
stress .sedative
- :Emotions limbic System
Amygdala
.Hypothalamus
.
exogenous
opoids :
. :agonist
.
)codeine
.(propoxyphene
www.syrianclinic.com
. - ) ( : :pentazocine
kappa mu .delta
) kappa naloxone . :antagonists mu
naltrexone(.
&$:
Bayer
.
)
(
.
.
.OB A2T/
:Acute intoxication and overdose
.
.
) meperidine (.
) (.
.
www.syrianclinic.com
.
)(.
:
vasoconstiction
dysphoria
insomnia
tachycardia
.
:Treatment 2C
. : methadone
: peak -
. .
:Clonidine . 2 )
( .
&'()*+# Hormones
-
-
-
-
-
:
1- (GHRH) Growth hormone- releasing hormone
www.syrianclinic.com
:
1- (GH) Growth hormone .
2- (TSH) Thyrotropin .
3- (FSH) Follicle-stimulating hormone
4- (LH) Luteinizing hormone .
5- (PRL) Prolactine .
6- (AcTH) Aderncortictropin .
7- (-LpH) - Lipotropin .
:
1-3 min
.
Octreotide
8
45
1.7 hour
1-3 min
www.syrianclinic.com
80 . -
: mg 5-200 8
acromegaly
achlorhydria syndrome
diabetic diarrhea, . carcinoid syndrome,
gastrinoma .Glucagonoma
: . Octreotide
: .
: bradycardia
B12 .
:
$ 3T7 : A7 t7 4Y_ . u3T7 A
A: 7 -
t 4Y $ u
$ 5- 7 .
M
- : E
-
$ U0T7
;] V^ -
BP U0T7| - 4Y
. A:T
% J
A
:
BC
anti-insulin x$
activity
2
Y: Q
^ 4Y 0- $ V
U:
BC $3T7A
>
^ 4Y7
www.syrianclinic.com
0:A 2
Q: t^ 4Y]. -
Y -7
A
:hypersecretion of GH A7;O |
O
-7] ) 4Y 4[
A! U $- $-- ;
. ( t
I # @ hyposecretion of GH #$
GH- ^$
2- AA 4Y m]
| m
] -6 t
GH>
( ] t m+ :A GH ( 4Y>B+
^- ) 7
! ( .
GH Recombinant human GH
GH E.coli
.
20-25 : .
GH
(IGF-I) Somatomedins ) (IGF-II
Somatomedins
.
0.25 mg/Kg 0.45 mg/Kg
.
0.2mg .
: gynecomastia
myalagias . arthralgias
FSH -7 : LH
: :
: FSH .
:LH
:FSH
androgen-binding
.globulin
.
: LH .
www.syrianclinic.com
-8D
Prolactin:
$
- @ $ s
|A UT 7 GH t +
@A
$>[ ; $; m4
$^- $ 7 lactotrophs 2
-
: Q >
$ t :!
7 $>
!7 !
7
- T > 4Y $ A
3
A
T +
A
] .A7
BC 2
4^- -PQ
3T70
Y 5A:2
Q:
t7 t : A-
U 2
Y:>[ . lactation.
-:
>
6 -7
$ 7
; 5T t : 4Y 50
` 4Y . 47> B+ ;
J >
$
u m5
+ 3PA >
$ - $ 2^- .7
- :oxcytocin
www.syrianclinic.com
.
.
( )
) 2-3min (
.
:
) ( .
:
OT receptor binding
phospholipase C
IP3, Ca2+
contraction of uterine smooth muscle and mammary
myoepithelial cells
-2 ) vasopressin : ( ADH
Phe - Tyr Cys
Glu - Asn - Cys - Pro - Arg - Gly - NH2
) ( :
V2
.
:
osmolality .
.
) (.
- . The renin-angiotensin II system II
.
V1 .
:
www.syrianclinic.com
Thyroid Hormones
: T4 T3
Z1
.A] 4Y ;5 m -7
$] T3 $ A] T4 6- -^;
T3 $ 15 5]T 7 T4 3
.BC
T4 $ 5 P Y T3
.0:A 7 4Y T3 2 T4 Q B :
:
+ 70 2
+-6 6- -^ 0 4Y 6 :Cretinism A (a
.
:Adult hypothyroidism $^N -N7
- 6 (b
2-3 50g .
.(100-200g/day)
.Nontoxicgoiter 4A ( - (c
.Papillary carcinoma of thyroid 4A : 6- O (d
:M L*
.- 6- -^ T y -
$N -N N NY 4NY NY N Thyrotoxicosis GZMi iD N
.Toxic nodular goiter 4A - - Grave :$
IgG NN $NN NN|A NN! 3NN QNN 4
NN7 NN NN : Grave
NN
tNN NN6- NN 4NN
3NNT7 TSH
NN 2NN Antibodies
. TSH 4Y -: J!
5]NNT -NN N NNY
NN : Toxic nodular goiter 4AN -N -N
.TSH _: $
5
: u
| :
A
. Carbinazole Methinazole (Tabazole)Propylthiouracil (PTU)
www.syrianclinic.com
7
M :
. m
A
-7? AY ATA; J.t :
ii NN6 : ii
a )!
NN-NN >-
NN NN0A (-NN ! /NN;O >g
;A. 5
a:
(20-30 mg) B (50-100 mg) Propylthiouracil
.(5-10mg) Methinazole
.(5-15mg) Carbinazole
(2*L )
#+ ( : Ionic inhibitor
3P
] @Y
N -N 2N^-N - N6 VN
5NBA NuNT JN
-
4@
3P70 T3 . T4
. -NO3 -ClO4 -SCN : P ] $
+ -
- .
(3
#
##) M M#
# ## # #z M(:
( -] - - ] U7 P0PA
4Y
.BC
(4
# : A+
127I ) 131I s 8 A P
A
>(.
) 123I s 13 A >
-( ) 125I s 60A(.
r 0131I x I !A .
!A $ ( 0.5-2 mm ) .7
- 6 @ 131I 2 ) + Necrosis7 .(Fibrosis s
(5 :
; 4Y -Y u - 7
Y $ Y .
6 -
MU GI: a
-1P -:) 40 T3 .( T4
www.syrianclinic.com
:Hyperthyroidism M I -B
.t [ -2 +
!;-1 :
. -4 .: T -3
.y I t -5
. -6
.;; PAO -7
N N; -N 4NY N:( T4) N ; :
U+
.TSH
: a
.(JTA +Y A )- | -1
.u -2
: .+
ZM M0{
.( UI )Grave disease -1
: Goiter - -2
4NN
T4 T3 70NN m7NN NN mNN> NN 4NNY
( - Y )
4 N J!;
: 7 -^
NNNN6- -NNNN^ 2NNNN TSH
-NN^ NN| 2NN@ NN ?NN
. Hypertrophy6-
GH ?# *CD#
<
#d
:
-1 .Type I
-2 Type II )
(.
-3 *.
-4 .Hyperglycemic emergencies
-5 )
(.
: DNA ) ( Recombinant DNA
bovine ** porcine
.
hexamer
dimer monomer .SC
parenterally
.
) ( .
.
elimination half-life .
% .
fluctuation
peak timing ) .(pharmacokinetics
*
A |Y ] ; -7
A t 5A:| > $ $]7 .$7u
** +I Py $T
U7
s _A: 47.-
www.syrianclinic.com
- : /
:(Lispro) Ultrafast/ultra short-acting analogue
* hexamer
.
infusion . )
( Peak
.
>
9.
Ultra fast/ultra lispro
short-acting
regular
Short-acting
[Plasma [Insulin
Intermediate- NPH
acting
lente
Long-acting ultralente
glargine
Ultra long-acting
* ) 28 (29
www.syrianclinic.com
* .
** 21 B 30
www.syrianclinic.com
$ &C >
9.
intermediate-acting
. intensified regimen
.pump .
: Hypoglycemia Type I
) ( ) (.
: Allergy and resistance to insulin
.
/ ) ( : Lipohytertrophy
*.
regular
lente
am pm am
&C > `I
9.
* .
www.syrianclinic.com
.H +&A O I +
. Inhalable insulin
: amphiphilic
.
:gene therapy
. -
O
C NH ( )
HN O
S
O .
O
N N
N H
CH 3
:secretagogue
. Nateglinide RepaglinideSulfonylureas
:Insulin sensitizers
.Thiazolidinedione Biguanides
:
.Miglitol Acarbose
secretagogue O >
9.
.Sulfonylureas: A
:
K+ ATP
B
.
tolbutamide .
) potency ( :
: Glipizide 2-4 )(
extended-release
. preparation
) :Glyburide (Glibenclamide 6 24
)( .
0:Glimepiride M s 5A
t] -
2 ( Y$]A
0 c - t 4Y | .$
www.syrianclinic.com
:
: .
) (.
Erythema .
.
:
surgery Severe stress or trauma
.
Eqv. Dose Duration Active
)(mg )(h metabolites
Tolbutamide 1000-1500 12-24 Yes (p-OH
)derivative
Chlorpropamide 250-375 24-60 Yes (2-OH and
)3OH groups
Tolazamide 250-375 12-24 No (4-COOH
)derivative
*
JA! 4Y>:
- y 4Y $A.u
www.syrianclinic.com
Third generation
Glimepiride 1-2 24 Yes (-OH on CH3 of
)R group
Repaglinide .B :Nateglinide
UI 7 M$
Q]A 7 A 0 Y 5 4Y^ .- $
$ r
T +Y M$0
*
57Y -D>g . 5 BCT A + BC ; 5Y
+; 4 - BC J
- 6 BC ? V J 20! J7A; ] - -! .postprandial
.A : Biguanides
French lilac guanidine
N H
H 2 N N H 2 : Phenformin
) ( Lactic acidosis
.
: metformin
.
:
gluconeogenesis Glucose-6-
phosphorylase .
. LDL
) HDL ( . Type II .
: .
*
www.syrianclinic.com
. ( TZD) Thiazolidinediones : B
.
:
: rosiglitazone 99% .
CH 3 3-499% .
N N S O
O
4-8mg.
NH
ROSIGLITAZONE O : pioglitazone
)(BRL-49653
3-7 16-24
> 99%
S O
O
N 15-45mg/day
NH
PIOGLITAZONE O
.
-
glucosidase
.
)
(.
Acarbose ) 1%
( . .
www.syrianclinic.com
. :
&T*D# :M
.Alkylating agents ]@A 5 -1
.Alkaloids - -2
.Antimetabolites | >
-3
.Antibiotics :| A -4
.Enzymes A -5
.Hormones + -6
.Platinum compounds $ -7
.New anti cancerP-: O -8
Alkylating agents %T #
.Nitrogen mustards
.Nitrosoureas
.Methane sulfonic acid esters
.Triazines
.Ethyleneamines
www.syrianclinic.com
: D
.(R ?u 0 +7 AY s
)A
A
T $ 4
A
.Cyclophosphamide
.Ifosphamide
. Chlorambucil
.Melphalan
N;A N $]!N -N N|
4Y 4
T 5A
.
:M
$NN m
NN DNANN 4NNY ?NN: NNA $NN]A
.5]@A u
Alkaloids M#
: Vinca alkaloids ]7; - 6
.Vincristine $
]7; -
.Vinblastine $
7; -
NNN 3NNP 2NNN
-NN 5NNNA :ii
ii
!
$NNNN
$NNNN 4
NNNN7 NNNN+O NNNN
.tubulin
$-NN NN: $NN sCNN
NN;A $NN
5]NT Ng $N JN JNA
u $]A subunits
N 5]NNT
ANN NNB $NN Dimer NNA
5NNNNNNN7 NNNNNNN 4NNNNNNN
)microtubules * NNNNNN^A
.( >7B 40^
( 4+Y ]@A 5 M0 2
5A
O - Y
.
: D
: Vincristine $
]7;
www.syrianclinic.com
c-Nu N]7; -N 6 JN NA 4N r
NT N| ( Paclitxel) Taxol :
.A 4Y 4^ A J 3
Antimetabolites <D z
bone marrow N 4NN 5NNP
N ANN7A N NNA 3NNP N+7]A NN c?N
.4A|+ +u 4Y 0
2NN
B@NN QNN NN7 NNA: 70NN NN A
4NNY *
NN >NN| 5-NN
.$- $ 70
.Antifolates >Y 4
( a : BP
.Purine analogs $ : (b
.Pyrimidine analogs $- : (c
:(Methotrexate) Antifolates D#I G( a
NA: N ]70N >N| NA $ Folic acid V_ ;A
4NNNY NNNA NNN U
NNN tNNN QNNN )7-NNN NNN7 5NNNP NNN7
4NNY t
NN tNNu $NN] (5NN
A 5NNP -NN NN NN
NN: NN 5NN
NN;
dihydrofolate
-NNN> Y-NNN+ N N 0NNN> Y-NNN
2NNN
N 0N -N VNY -N -N VN_ ;NA 5N: -N VN ) reductase
.(UT
VY-N+ CN N >2N
N6 -N VY-N+- 7 UT
A
. 4Y 7 A: 5]T 50 A U0P
-
$NN
Aminopterin $
NN7 : -NN VNN ;NN NN7 +NNTA $NN
.Amethoperin
: D
.gestational choriocarcinoma 4 A: ATA O
4Y -
acute lymphocytic leukemia in ;O -7
:; A -
| -
. ]-7
- | u 4Y -: cBC $] children
www.syrianclinic.com
: D
www.syrianclinic.com
Antibiotics #
7 z
5]NT N c?N B@ Streptomyces - Bu $ :| A c?
: c? $ . 2
4
>
NA DNAN $ ^3 :(Actinomycin D) Dactinomycin $7
B@NN RNA polymerase NN UNN0P
DNANN $NN RNANN NN 3NNP
.DNA 70 2
u
ribosomal 4N RNAN $N] NN c?N+ BCN
RNAN N JNA!
. c?+ P RNA
chelator t
NN NNA NN :7A -NN
^ ]$NN :Bleomycin $NN
.DNA 0: 2
: Fe --: 3 A
.RNA 70 U
70 3P DNA 3 :Adriamycin $
: D
pediatric solid N;O -N7
N N 4N 5]NT $N7
5A
N
.tumors
Enzymes
N 2N L-asparagine $!N N ? UA : :L-asparaginase -1
.L-aspartate
$!N 70N 2N
N6 ( O _ 4Y ? Y $A]
?N rN0 -N Nu $N UN
5N:
Y (P7N $!N N 2N
N+
-)
N+ QN ON N_ N $N +N -N? N N $N] .U7 +: @ -
.$! $
[
>4Y Cu $]A $!! :
acute lymphocytic NN: NN;A -NN NN| 2NN
NN
6 NN c?NN A
NN
.leukemia
www.syrianclinic.com
Hormones #N
GLUCOCORTICOIDS
ESTROGENS
ANTIESTROGENS
Androgen antagonists
N;A N BN] 3NP :GLUCOCORTICOIDS] - ]]-1
.;A - | 5A
JN7A N+ QN
N O 4Y 5A
: ESTROGENS7! >
-2
-NP ON NuA N -
N .4 J!
$!- 5]T
.C $ -
N 4Y7 $;
: ANTIESTROGENS$! | >
-3
.-P O 4Y -P B]
3P
47!-NNN NNN Flutamide : Androgen antagonists$!-NNN NNN -4
.
O 4Y -
. O -
!
-
.(c- 20 >) A7 + 3P +Y $
UT :Octerotide -
Platinum compounds
<
N
N 2N
NA c?N+ 5N BC
sT
U! O A JA!
6 + Q
.
P
] -
:Cisplatin $ x; 0 c? $
QNNN NNN ]@A 5NNN BCNNN NNN UNNNT cBCNNN NNNg
. Y ] 7 U
7 4Y ] 4I -
NNN
3NNN UNNN 5]NNNT DNANNN 3NNN NNN+Y
.U 50 Cross-links
-
NN ?NN NN NN6 NNu $NN xNN NNBg
$NN NN -
NN NN NN JNN NNTA
.Carboplatin $ ]5P BC s
: D
:
$ 5A
.$
7; $ J TA : testicular cancer$
O
. bladder cancerPA O
.5 ; $ TA : 6 O
www.syrianclinic.com
*
.-
A ; U0P
Y[y DNA 70 3P
- ?
www.syrianclinic.com
!
<U B: Resistance Mechanisms
-6]N A N- N-N
tN Y N-N 2N0A ]
N QNN NNu
g A - :5P
- 5- .
-NNN ; NNNNNN` u Y-+
NNNA :NNN 7-NNN NNN $NNN 3-NNN: JNNN6A $NNN
DNA
;O - J7A - ?+ .J6A
-g 3NNNT7NNN NNN NNN -A[ NNNANNN
3NNNP 4NNN +
70NNN
BCNNNNNN
)
-Y V - !.($
A : A -6 DNA / C0 U
. P :Dietary Cholesterol
) ( C27H45OH
.
1gr
.
400mg 200mg
) 1gr 800mg
.(de novo synthesis
www.syrianclinic.com
.
."0, :lipoproteins
Complexes
. lipoprotein
)
(exogenous
)
.(endogenous
)
)
apolipoprotein - apoproteins(.
. ."0,:
apoprotein )
.(ultracentrifugation
:
==
A1@
:chylomicrons
100-1000nm
Apoprotein
) (A,C,E
Apoprotein B48
.
Very Low-Density
$AF1 E
= BC
") 0 )(VLDL
:Lipoprotein
) ( TG 30-80nm
.B100
www.syrianclinic.com
VLDL ILD . LDL
$AF1 G0 )
E
=:Low Density Lipoprotein (LDL) BC
bad choleserol 20-30nm
.AII LDL
.
LDL .100mg/dl
$AF1 HIA
E
=:Intermediate-Density Lipoprotein (IDL) BC
VLDL .LDL
$AF1 ;
9 E
=:High-Density Lipoprotein (HDL) BC
nm 20 -7
HDL .40mg/dl
LP(a) lipoprotein
."0:9
endogenous .exogenous
-H g':Exogenous S
TG
Lipoprotein Lipase uptake .
)
(
Chylomicrons
) remnants
(
www.syrianclinic.com
) (30-50nm remnants
hepatocyte Endocytosis
) (.
bile acids
.VLDL
-H g+: Endogenous 0
VLDL
) ( .
IDL
) LDL (
.
LDL Endocytosis LDL
LDL
LDL coated vesicles Endosomes
) PH( LDL
.
LDL ) (
.
.LDL
LDL
.
.HDL
www.syrianclinic.com
F+!
E$ J LDL
=!
A:
)
(HMG-CoA reductase ) (ACAT
.LDL
SREBP
DNA
RNA
.LDL
:
)
(statins LDL
.
/ .G + :Dyslipidimia
Dyslipidimia primary :seconadry
www.syrianclinic.com
atorvastatin resins
.
<@"
A@C 0 A#L
:
) ( :
:DM .
:hyperthyroidism
.
:Birth Control Pills
) (.
) protease inhibitors
(AIDS .
:
.(Atorvastatin, Pravastatin, Lovastatin) Statins
.(Gemfibrozil and Fenofibrate) Fibric Acid Derivatives
www.syrianclinic.com
LDL LDL
.LDL
. HDL
atorvaststin . HMG-CoA Reductase
3
, B:
) expression endothelial :eNOS
(nitric oxide synthase .nitroc oxide
www.syrianclinic.com
6+:
.
) lovastatin and (simvastatin prodrug
.
: ) (% .
- atorvastatin T1/2=14
hrs
3 2":
HMG-CoA Reductase
:
.
)
(.
.teratogenic
"I
!:
:
.
.
VLDL
10% LDL 10% .HDL
Peroxisome preliferator-
activated Receptor (PPAR)
) (
apo A-I apo A-II .HDL
www.syrianclinic.com
3 2":
.
. arrhythmias
myopathy
.
hypokalemia .
.cholesterol gallstones
)"H:
.
.
))C
:
) (
.VLDL
www.syrianclinic.com
colestyramine colestipol
.
LDL ) (upregulation
LDL LDL .
:
HDL .
: .
3 2":
systemic toxicity
abdominal bloating
) (.
unappetizing .
+& +:
) (A, D, E, and K
.
www.syrianclinic.com
))C
:
)
(.
.
B 3
OB^.
. k. ,:,
\
:
VLDL
LDL
.
HDL . AI, AII
.LPL
LDL-Cholesterol
3 2":
flushing palpitations .
.hyperuricemia
.peptic ulcer disease
)
(.
6+:
-.
.
)"H:
.
www.syrianclinic.com
:Ezetimibe
:
.
cholesterol pool
LDL LDL .
)'+
:
.
.
)"H:
.
.hypercholesterolemia
www.syrianclinic.com